Monopar Therapeutics
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
MNPR$71.78-2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 3. Legal Proceedings
We are currently not, and to date have never been, a party to any adverse material legal proceedings.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.